ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06744647
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06724809
- Locations
- 🇨🇳
Research Site, Wuhan, China
PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06677138
- Locations
- 🇨🇳
Research Site, Shanghai, China
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06607627
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06578949
- Locations
- 🇨🇳
Research Site, Wuhan, China
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06449001
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06312644
- Locations
- 🇺🇸
North American call center (NACC), Boston, Massachusetts, United States
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06291376
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT06208488
- Locations
- 🇨🇦
Research Site, Laval, Quebec, Canada
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06183931
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath